Une vision stratégique de l'actualité scientifique et technologique du secteur des biotechnologies.

Billets par Aline Aurias

Three questions to Jean-Dominique François

International Technical Expert at the JST Coordinator of the French Tech in Japan Correspondent of Hello Tomorrow in Japan

Euglena, from algae to food, biofuel and beyond

Exploiting the huge versatility of Euglena gracilis compounds, Euglena Corporation is mass producing algae based products, attempting to create a carbon cycling society in the process.

3 Questions à Jean-Dominique François

Expert Technique International auprès de la JST Coordinateur de la French Tech au Japon Correspondant Hello Tomorrow au Japon

Figures – Biotechnologies & Health in Japan

Japan Gross Domestic Product 2016 was about $4.9 trillions (7.97 % of the world economy). –Japan has been ranked 16th by the Global Innovation Index 2016: • 9th for the proportion of researchers in general population: 5.4 for 1.000 inhabitants • 15th for academia/industry cooperation • 3rd for its R&D intensity : 3.59% of its […]

The biotechnology sector in Japan

With a tradition of fermentation and a strong dependence on imports of food, oil and industrial feedstock, Japan became interested very early on in the potential that biotechnology offered. As early as the 1970s, the Japanese Ministry of International Trade and Industry stated its intent to place the development of life sciences and biotechnology at […]

CELLforCURE, a feedback on Japan

CELLforCURE is a pharmaceutical company specialized in the industrial production of cell and gene therapy medicines. Founded in 2010, it operates since 2013 Europe’s leading industrial platform in terms of capacity. CELLforCURE has operated as a CDMO with several Japanese companies since its creation. Interview with Sébastien Renouf, Director of Pharmaceutical Affairs and Deputy Managing […]

Japanese Life Sciences research and innovation ecosystem

Not unlike France, Japan is struggling to value its academic research, despite its high quality. While its strong industrial research is still reluctant to open up to external influences, the public and private sectors are well aware of the importance of developing a more collaborative research practice.

AMED, for a better allocation of research ressources

AMED, the Japan Agency for Medical Research and Development, has been created in April 2015 to provide a unified funding allocation for medical research expenses which were previously scattered between MEXT, MHLW and METI. This unifying action aims at optimizing resources distribution to establish and maintain coherent research environments throughout Japan.

Portraits of Japanese start-ups

Cyclodextrin based drug development and health food Cyding was born in April 2016. This pre-seed start-up, originated from Kumamoto University (Kyushu), is building off studies on cyclodextrin to enhance the solubility and bioavailability of hydrophobic compounds. The company develops drugs and drug delivery carriers for oncology and gene therapy, and wishes to extend its knowhow […]

Japanese clusters, a broad concept

In Japan, the definition of cluster is not as restricted as in France or Europe. One can find some cluster organisation that closely match their Western counterparts, where an independent institution promotes and supports cooperation between companies, R & D centers and universities within the same region and in their international activities.

Dernière Lettre parue

Cliquez sur l'image pour accéder à la lecture via Calaméo (accès réservé aux abonnés)
Cliquez sur l'image pour accéder à la lecture via Calaméo (accès réservé aux abonnés)


(abonnement aux éditions de la Lettre et accès intégral au site)

Abonnez-vous à notre newsletter gratuite

Chimie et Biologie de Synthèse : les Applications